Survival outcomes of stenting outflow graft stenosis in continuous-flow left ventricular assist devices: a systematic re
- PDF / 407,981 Bytes
- 8 Pages / 595.276 x 790.866 pts Page_size
- 29 Downloads / 155 Views
Survival outcomes of stenting outflow graft stenosis in continuous-flow left ventricular assist devices: a systematic review Chelsey T. Wood 1 & Thomas J. O’Malley 1 & Elizabeth J. Maynes 1 & Alec Vishnevsky 2 & Rohinton J. Morris 1 & Louis E. Samuels 1 & H. Todd Massey 1 & Vakhtang Tchantchaleishvili 1
# Springer Science+Business Media, LLC, part of Springer Nature 2019
Abstract Stenosis in the continuous-flow left ventricular assist device (CF-LVAD) outflow graft is caused by various factors. We discuss indications for percutaneous intervention of outflow graft complications and evaluate the use of this treatment in re-establishing adequate CF-LVAD flow. An electronic search was performed to identify all studies in the English literature reporting CF-LVAD outflow graft stenting. Twenty-one studies consisting of 26 patients were included. Patient-level data were extracted for statistical analysis. Median patient age was 59 years [45.8–67.0] and 65.4% (17/26) were male. 58.3% (14/24) of patients had HeartWare HVAD, 37.5% (9/24) had HeartMate II LVAD, and 4.2% (1/24) had HeartMate III LVAS. Median time from device placement to outflow graft stenting was 24.0 months [7.8–30.4]. 76.9% of patients (20/26) presented with heart failure. Complications of the CF-LVAD outflow graft included thrombosis in nine patients (34.6%), stenosis in nine patients (34.6%), kinking in three patients (11.5%), pseudoaneurysm in one patient (3.8%), external graft compression in one patient (3.8%), and bronchial-arterial fistula in one patient (3.6%). Immediate flow improvement occurred in 23/26 patients (88.5%), with the remaining 11.5% (3/26) requiring additional procedures. Pre- and post-intervention flows were 2.9 L/min [2.0–3.5] and 4.7 L/min [4.1–4.8] respectively (p = 0.01). Of patients, 96.2% (25/26) were discharged with a median time to discharge of 4 days [3.0–5.0]. The 30-day mortality was 6.7% (1/15). Overall mortality during the median follow-up of 90 days was 9.5% (2/21). Outflow graft stenting appears to effectively alleviate CF-LVAD outflow graft obstruction and is associated with low overall mortality. Keywords : Left ventricular assist device . Outflow graft . Stenting . Endovascular intervention . Stenosis
Introduction Heart failure continues to be a significant source of morbidity and mortality, and incidence rates are expected to double over the coming years [1, 2]. Heart transplantation has been the gold standard for patients who develop end-stage heart failure that is refractory to guideline-directed medical therapy [3]. However, the ability to offer transplantation is limited by a finite qualified donor pool [4]. Continuous-flow left ventricular assist devices * Vakhtang Tchantchaleishvili [email protected] 1
Division of Cardiac Surgery, Thomas Jefferson University, 1025 Walnut St, Suite 607, Philadelphia, PA 19107, USA
2
Department of Cardiology, Thomas Jefferson University, Philadelphia, PA, USA
(CF-LVAD) were initially developed as a bridge to transplantation, but since the initial f
Data Loading...
